152 related articles for article (PubMed ID: 36401784)
1. Current childhood chronic myeloid leukemia management under tyrosine kinase inhibitor treatment.
Karadaş N; Göktepe ŞŞÖ; Baş İ; Ece D; Özdemir HH; Balkan C; Kavaklı K; Aydinok Y; Karapinar DY
Int J Hematol; 2023 Mar; 117(3):446-455. PubMed ID: 36401784
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia.
Shima H; Kada A; Tanizawa A; Sato I; Tono C; Ito M; Yuza Y; Watanabe A; Kamibeppu K; Uryu H; Koh K; Imai C; Yoshida N; Koga Y; Fujita N; Saito AM; Adachi S; Ishii E; Shimada H
Pediatr Blood Cancer; 2022 Aug; 69(8):e29699. PubMed ID: 35403816
[TBL] [Abstract][Full Text] [Related]
3. [Analysis on tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia in the real world: experience from single center].
Yu L; Qin YZ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):754-760. PubMed ID: 29081191
[No Abstract] [Full Text] [Related]
4. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
[No Abstract] [Full Text] [Related]
5. Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania.
Robin JB; Theron A; Quittet P; Exbrayat C; Gaillard JB; Lavabre-Bertrand T; David S; Saad A; Jourdan E; Cartron G
Ann Hematol; 2022 May; 101(5):1015-1022. PubMed ID: 35278099
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
Iino M; Yamamoto T; Sakamoto Y
Hematology; 2019 Dec; 24(1):355-361. PubMed ID: 30880635
[TBL] [Abstract][Full Text] [Related]
7. Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.
Fava C; Rege-Cambrin G; Dogliotti I; Cerrano M; Berchialla P; Dragani M; Rosti G; Castagnetti F; Gugliotta G; Martino B; Gambacorti-Passerini C; Abruzzese E; Elena C; Pregno P; Gozzini A; Capodanno I; Bergamaschi M; Crugnola M; Bocchia M; Galimberti S; Rapezzi D; Iurlo A; Cattaneo D; Latagliata R; Breccia M; Cedrone M; Santoro M; Annunziata M; Levato L; Stagno F; Cavazzini F; Sgherza N; Giai V; Luciano L; Russo S; Musto P; Caocci G; Sorà F; Iuliano F; Lunghi F; Specchia G; Pane F; Ferrero D; Baccarani M; Saglio G
Haematologica; 2019 Aug; 104(8):1589-1596. PubMed ID: 30819917
[TBL] [Abstract][Full Text] [Related]
8. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
[TBL] [Abstract][Full Text] [Related]
9. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
Wright MP; Shepherd JD; Barnett MJ; Nantel SH; Sutherland HJ; Toze CL; Hogge DE; Nevill TJ; Song KW; Abou Mourad YR; Narayanan S; Power MM; Smith CA; Forrest DL
Biol Blood Marrow Transplant; 2010 May; 16(5):639-46. PubMed ID: 20005967
[TBL] [Abstract][Full Text] [Related]
10. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
[TBL] [Abstract][Full Text] [Related]
12. [Tyrosine kinase inhibitors discontinuation for chronic myeloid leukemia: a multicenter retrospective analysis in China].
Zhu XJ; You Y; Duan MH; Zhu Y; Liu BC; Chen SN; Du X
Zhonghua Xue Ye Xue Za Zhi; 2018 Dec; 39(12):994-997. PubMed ID: 30612400
[No Abstract] [Full Text] [Related]
13. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
Legros L; Nicolini FE; Etienne G; Rousselot P; Rea D; Giraudier S; Guerci-Bresler A; Huguet F; Gardembas M; Escoffre M; Ianotto JC; Noël MP; Varet BR; Pagliardini T; Touitou I; Morisset S; Mahon FX;
Cancer; 2017 Nov; 123(22):4403-4410. PubMed ID: 28743166
[TBL] [Abstract][Full Text] [Related]
14. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
Naqvi K; Jabbour E; Skinner J; Anderson K; Dellasala S; Yilmaz M; Ferrajoli A; Bose P; Thompson P; Alvarado Y; Jain N; Takahashi K; Burger J; Estrov Z; Borthakur G; Pemmaraju N; Paul S; Cortes J; Kantarjian HM
Cancer; 2020 Jan; 126(1):67-75. PubMed ID: 31553487
[TBL] [Abstract][Full Text] [Related]
16. Relevance of treatment-free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors.
Etienne G; Faberes C; Bauduer F; Adiko D; Lifermann F; Dagada C; Lenoir C; Schmitt A; Klein E; Fort MP; Bijou F; Turcq B; Robbesyn F; Durrieu F; Versmée L; Madene S; Moldovan M; Katsahian S; Charles-Nelson A; Lascaux A; Mahon FX; Dulucq S
Cancer Med; 2021 Jun; 10(11):3635-3645. PubMed ID: 33988316
[TBL] [Abstract][Full Text] [Related]
17. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
[TBL] [Abstract][Full Text] [Related]
18. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data.
Zhu G; Yang Y; Wang H; Xie J; Hu J; Guo W; Zhang L; Liu Z; Chen X; Chang J; Xu J; Tan Y
Ann Clin Lab Sci; 2020 Sep; 50(5):591-599. PubMed ID: 33067205
[TBL] [Abstract][Full Text] [Related]
19. Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.
Sogawa R; Kimura S; Yakabe R; Mizokami Y; Tasaki M; Sueoka-Aragane N; Narisawa Y; Kimura S
Int J Clin Oncol; 2018 Oct; 23(5):974-979. PubMed ID: 29651584
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution.
Cerveira N; Loureiro B; Bizarro S; Correia C; Torres L; Lisboa S; Vieira J; Santos R; Pereira D; Moreira C; Chacim S; Domingues N; Espírito-Santo A; Oliveira I; Moreira I; Viterbo L; Martins Â; Teixeira MR; Mariz JM
BMC Cancer; 2018 Dec; 18(1):1245. PubMed ID: 30541488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
